The leading therapy for alpha₁-antitrypsin deficiency (AATD)
Proven. Trusted. Prescribed.
For more than 35 years, PROLASTIN-C LIQUID has been the most prescribed alpha-1 augmentation therapy, trusted nationwide.1,2 Augmentation therapy is proven to effectively raise alpha₁ antitrypsin (AAT) levels in patients with alpha-1 that help keep neutrophil elastase in check.1
The PROLASTIN DIRECT® program: Benefits for patients beyond treatment
PROLASTIN DIRECT is one source for the needs of every patient with alpha-1.
Why HCPs choose PROLASTIN-C LIQUID
With more than 35 years of clinical use, PROLASTIN-C LIQUID has earned the trust of HCPs nationwide. More than 4 million infusions delivered worldwide, reinforcing a legacy of safety and trust.2
Simple Process and Short Preparation Time
Each vial arrives ready to infuse without the need for reconstitution1,3
Fast Infusion Time
It takes approximately 15 minutes-with an infusion volume of 20 mL/g
Stable
For up to 2 years when refrigerated, and for 1 month at room temperature3
Proven Safety Profile
Most common adverse reactions being diarrhea and fatigue (6%)1
“I’m very impressed with the PROLASTIN DIRECT program. As a provider, it allows office visits to be truly patient-focused, not paperwork-driven.”
Start your patients on PROLASTIN-C LIQUID with confidence
What is alpha₁-antitrypsin deficiency (alpha-1)?
Alpha₁-antitrypsin deficiency (alpha-1) is the #1 known genetic risk factor for COPD and may be a contributing cause in approximately 3 in 10 cases of COPD in the United States.4,5
Support your patients LIKE A PRO with PROLASTIN DIRECT®
PROLASTIN-C LIQUID is available through the PROLASTIN DIRECT program.
Frequently asked questions
PROLASTIN-C LIQUID is an alpha₁-proteinase inhibitor (human) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 antitrypsin (AAT).1 Augmentation therapy is proven to effectively raise alpha1-antitrypsin (AAT) levels in patients with alpha-1 that help keep neutrophil elastase in check.1
PROLASTIN‑C LIQUID is administered as a once-weekly intravenous (IV) infusion at a dose of 60 mg/kg body weight. The product is ready to use—no reconstitution required.1
PROLASTIN-C LIQUID should be given intravenously at a rate of 0.08 mL/kg/min as determined by the response and comfort of the patient.1
To start treatment, download, complete, and fax the enrollment form for PROLASTIN DIRECT to 888-817-2098. Once prescribed, your patient gains immediate access to all the benefits of the PROLASTIN DIRECT program.
PROSLASTIN-C LIQUID is available only through PROLASTIN DIRECT.
PROLASTIN DIRECT provides personalized support to help patients start and stay on therapy. The program offers support in a variety of ways including counseling and coordination from nurses and pharmacists specializing in alpha-1, insurance and access assistance including prior authorization and reimbursement support, and financial assistance for eligible patients through the Grifols Assist program, which offers up to $10,000 annually.
The most common adverse reactions observed in more than 5% of patients during PROLASTIN-C LIQUID clinical trials were diarrhea and fatigue.1 Hypersensitivity reactions, including anaphylaxis, may also occur.
Patients should be closely monitored throughout the infusion, and treatment should be stopped if hypersensitivity symptoms develop.1
Important Safety Information
PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Limitations of Use
- The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available.
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.
PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.
Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).
Please see full Prescribing Information for PROLASTIN-C LIQUID.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
References
- PROLASTIN®-C LIQUID (alpha1-proteinase inhibitor [human]) Prescribing Information. Grifols.
- Data on file, Grifols.
- Barker AF, Campos MA, Brantly ML, et al. Bioequivalence of a liquid formulation of alpha-proteinase inhibitor compared with Prolastin®-C (lyophilized alpha-PI) in alpha-antitrypsin deficiency. COPD. 2017;14(6):590-596.
- Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with α1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.
- Han MK Martinez FJ. Host, gender, and early-life factors as risks for chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):329-337.